TMI is a biotechnology company committed to discovering, developing and commercializing novel and proprietary drugs to diagnose and treat human cancers having inadequate pharmaceutical alternatives. The company has built a strong technology platform around targeted therapeutics that bind only to specific cancer cell types.
ViaCell is a biotechnology company focused on enabling the widespread use of human cells as medicine. The company is developing a pipeline of proprietary stem cell product candidates intended to address cancer, cardiac disease, and diabetes. In addition, ViaCell's reproductive health business unit commercializes ViaCord®, a product that offers expectant families the option of preserving their babies' stem cells from umbilical cord blood. ViaCell was acquired by PerkinElmer in November 2007.
